Jedd Wolchok

Biography

Jedd Wolchok is a medical oncologist who specializes in the treatment of melanoma and whose research focuses on the development of innovative ways to use the immune system to treat cancer. His specific research interest is the pre-clinical and early clinical development of novel immunologic therapies. He has been a principal investigator in several pivotal clinical trials, including trials using plasmid DNA vaccines for patients with melanoma and a large phase III trial that led to the FDA approval of ipilimumab, an antibody now used as a first-line treatment for patients with advanced melanoma. He has been involved in the development of the DNA vaccine program at every level - from initial studies in mouse models, through all levels of regulatory review, and now as principal investigator of the clinical trials. He is an Associate Director of the Ludwig Center for Cancer Immunotherapy, an associate member of Ludwig Cancer Research, and the Lloyd J. Old/Virginia and Daniel K. Ludwig Chair in Clinical Investigation He is director of the CRI/Ludwig Cancer Vaccine Collaborative Trials Network, and is an associate director of the CRI Scientific Advisory Council. Dr. Wolchok has authored numerous articles concerning DNA vaccines, cytokine biology, and clinical care of melanoma and co-authored two chapters in the definitive textbook, Cutaneous Melanoma. Dr. Wolchok is also co-editor of the journal Cytotherapy.

Research Interest

Immunology